Antibiotic stewardship in the intensive care unit

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 2, 2011, Pages 215-227

  Arnold, Heather M ^a   Micek, Scott T ^a   Skrupky, Lee P ^a   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic stewardship; infection; intensive care unit

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFOTAXIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; MOXIFLOXACIN; POLYMYXIN; POLYMYXIN B; PRESCRIPTION DRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MOLECULAR DIAGNOSIS; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION; INTENSIVE CARE UNITS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 79955053526     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1275534     Document Type: Article

References (85)

1. Spellberg B, Guidos R, Gilbert D et al, Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008 46 2 155-164 (Pubitemid 351269151)
2. Kollef M H., Sherman G, Ward S, Fraser V J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999 115 2 462-474 (Pubitemid 29083057)
3. Micek S, Welch E, Khan J et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010 54 5 1742-1748
4. Arnold H M., Micek S T., Shorr A F. et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010 30 4 361-368
5. Zilberberg M D., Shorr A F., Micek S T. et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors. Infect Control Hosp Epidemiol 2009 30 12 1203-1210
6. Micek S T., Kollef K E., Reichley R M., Roubinian N, Kollef M H. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007 51 10 3568-3573 (Pubitemid 47519345)
7. Kollef K E., Schramm G E., Wills A R., Reichley R M., Micek S T., Kollef M H. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008 134 2 281-287
8. Arias C A., Murray B E. Antibiotic-resistant bugs in the 21st centurya clinical super-challenge. N Engl J Med 2009 360 5 439-443
9. Pakyz A L., MacDougall C, Oinonen M, Polk R E. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008 168 20 2254-2260
10. Kollef M H., Napolitano L M., Solomkin J S. et al. Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis 2008 47 Suppl 2 S55-S99, quiz S100-S101
11. Bhat S V., Peleg A Y., Lodise T P. Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007 51 12 4390-4395 (Pubitemid 350209894)
12. Tam V H., Gamez E A., Weston J S. et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008 46 6 862-867 (Pubitemid 351417187)
13. Soriano A, Marco F, Martnez J A. et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008 46 2 193-200 (Pubitemid 351269157)
14. Bhat S, Fujitani S, Potoski B A. et al. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents 2007 30 5 458-462 (Pubitemid 47498961)
15. El Amari E B., Chamot E, Auckenthaler R, Pechère J C., Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001 33 11 1859-1864 (Pubitemid 33105125)
16. Beardsley J R., Williamson J C., Johnson J W., Ohl C A., Karchmer T B., Bowton D L. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006 130 3 787-793 (Pubitemid 44423610)
17. Lancaster J W., Lawrence K R., Fong J J. et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy 2008 28 7 852-862 (Pubitemid 351875164)
18. Aarts M A., Hancock J N., Heyland D, McLeod R S., Marshall J C. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008 36 1 108-117
19. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004 328 7441 668
20. Heyland D K., Dodek P, Muscedere J, Day A, Cook D, Group CCCT Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008 36 3 737-744
21. Kumar A, Zarychanski R, Light B et al, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010 38 9 1773-1785
22. Schentag J J., Strenkoski-Nix L C., Nix D E., Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998 27 1 40-46 (Pubitemid 28334416)
23. Nicasio A M., Ariano R E., Zelenitsky S A. et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009 53 4 1476-1481
24. Van Wart S A., Andes D R., Ambrose P G., Bhavnani S M. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009 63 4 409-414
25. Roberts J A., Kirkpatrick C M., Roberts M S., Dalley A J., Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010 35 2 156-163
26. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008 36 4 1089-1096 (Pubitemid 351482655)
27. Patel GWPN, Patel N, Lat A et al. Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections. Diagn Microbiol Infect Dis 2009 64 2 236-240
28. Shafazand S, Weinacker A B. Blood cultures in the critical care unit: improving utilization and yield. Chest 2002 122 5 1727-1736 (Pubitemid 35366089)
29. Bates D W., Goldman L, Lee T H. Contaminant blood cultures and resource utilization: the true consequences of false-positive results. JAMA 1991 265 3 365-369
30. Ince J, McNally A. Development of rapid, automated diagnostics for infectious disease: advances and challenges. Expert Rev Med Devices 2009 6 6 641-651
31. Biedenbach D J., Moet G J., Jones R N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004 50 1 59-69 (Pubitemid 39360263)
32. Forrest G N., Roghmann M C., Toombs L S. et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008 52 10 3558-3563
33. Forrest G N., Mehta S, Weekes E, Lincalis D P., Johnson J K., Venezia R A. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother 2006 58 1 154-158 (Pubitemid 44294999)
34. Sgaard M, Hansen D S., Fiandaca M J., Stender H, Schnheyder H C. Peptide nucleic acid fluorescence in situ hybridization for rapid detection of Klebsiella pneumoniae from positive blood cultures. J Med Microbiol 2007 56 Pt 7 914-917 (Pubitemid 47047483)
35. Sgaard M, Stender H, Schnheyder H C. Direct identification of major blood culture pathogens, including Pseudomonas aeruginosa and Escherichia coli, by a panel of fluorescence in situ hybridization assays using peptide nucleic acid probes. J Clin Microbiol 2005 43 4 1947-1949
36. Peleg A Y., Tilahun Y, Fiandaca M J. et al. Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa. J Clin Microbiol 2009 47 3 830-832
37. Pfaller M A., Diekema D J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 1 133-163 (Pubitemid 46167771)
38. Trick W E., Fridkin S K., Edwards J R., Hajjeh R A., Gaynes R P., Hospitals TNNISS National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002 35 5 627-630
39. Pfaller M A., Diekema D J., Gibbs D L. et al, Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007 45 6 1735-1745 (Pubitemid 46933900)
40. Shepard J R., Addison R M., Alexander B D. et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008 46 1 50-55
41. Gherna M, Merz W G. Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol. J Clin Microbiol 2009 47 1 247-248
42. Alexander B D., Ashley E D., Reller L B., Reed S D. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006 54 4 277-282
43. Forrest G N., Mankes K, Jabra-Rizk M A. et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 2006 44 9 3381-3383 (Pubitemid 44413783)
44. Lehmann L E., Alvarez J, Hunfeld K P. et al. Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis. Crit Care Med 2009 37 12 3085-3090
45. Bloos F, Hinder F, Becker K et al. A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med 2010 36 2 241-247
46. Kilic A, Muldrew K L., Tang Y W., Basustaoglu A C. Triplex real-time polymerase chain reaction assay for simultaneous detection of Staphylococcus aureus and coagulase-negative staphylococci and determination of methicillin resistance directly from positive blood culture bottles. Diagn Microbiol Infect Dis 2010 66 4 349-355
47. Stamper P D., Babiker W, Alcabasa R et al. Evaluation of a new commercial TaqMan PCR assay for direct detection of the Clostridium difficile toxin B gene in clinical stool specimens. J Clin Microbiol 2009 47 12 3846-3850
48. Kvach E J., Ferguson D, Riska P F., Landry M L. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol 2010 48 1 109-114
49. Micek S T., Heuring T J., Hollands J M., Shah R A., Kollef M H. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006 26 2 204-213 (Pubitemid 43201868)
50. Eachempati S R., Hydo L J., Shou J, Barie P S. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009 66 5 1343-1348
51. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 171 4 388-416
52. Labelle A J., Arnold H, Reichley R M., Micek S T., Kollef M H. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 2010 137 5 1130-1137
53. Schlueter M, James C, Dominguez A, Tsu L, Seymann G. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010 38 5 357-362
54. Stoutenbeek C P., van Saene H K., Miranda D R., Zandstra D F. The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients. Intensive Care Med 1984 10 4 185-192 (Pubitemid 14071556)
55. van Nieuwenhoven C A., Buskens E, van Tiel F H., Bonten M J. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001 286 3 335-340 (Pubitemid 32656164)
56. de Jonge E, Schultz M J., Spanjaard L et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003 362 9389 1011-1016 (Pubitemid 37186877)
57. Krueger W A., Lenhart F P., Neeser G et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002 166 8 1029-1037 (Pubitemid 35178699)
58. de La Cal M A., Cerdá E, Garca-Hierro P et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. Ann Surg 2005 241 3 424-430 (Pubitemid 40299718)
59. Chan E Y., Ruest A, Meade M O., Cook D J. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 2007 334 7599 889-900
60. de Smet A M., Kluytmans J A., Cooper B S. et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009 360 1 20-31
61. Lingnau W, Berger J, Javorsky F, Fille M, Allerberger F, Benzer H. Changing bacterial ecology during a five-year period of selective intestinal decontamination. J Hosp Infect 1998 39 3 195-206 (Pubitemid 28362385)
62. Oostdijk E A., de Smet A M., Blok H E. et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010 181 5 452-457
63. Verwaest C, Verhaegen J, Ferdinande P et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 1997 25 1 63-71
64. Hammond J M., Potgieter P D., Saunders G L., Forder A A. Double-blind study of selective decontamination of the digestive tract in intensive care. Lancet 1992 340 8810 5-9
65. DeRiso A J. II, Ladowski J S., Dillon T A., Justice J W., Peterson A C. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996 109 6 1556-1561 (Pubitemid 26193384)
66. Segers P, Speekenbrink R G., Ubbink D T., van Ogtrop M L., de Mol B A. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 2006 296 20 2460-2466 (Pubitemid 44791202)
67. Fourrier F, Cau-Pottier E, Boutigny H, Roussel-Delvallez M, Jourdain M, Chopin C. Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients. Intensive Care Med 2000 26 9 1239-1247
68. Fourrier F, Dubois D, Pronnier P et al, PIRAD Study Group. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: a double-blind placebo-controlled multicenter study. Crit Care Med 2005 33 8 1728-1735 (Pubitemid 41153697)
69. Panchabhai T S., Dangayach N S., Krishnan A, Kothari V M., Karnad D R. Oropharyngeal cleansing with 0.2% chlorhexidine for prevention of nosocomial pneumonia in critically ill patients: an open-label randomized trial with 0.01% potassium permanganate as control. Chest 2009 135 5 1150-1156
70. Koeman M, van der Ven A J., Hak E et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006 173 12 1348-1355 (Pubitemid 43900709)
71. Tantipong H, Morkchareonpong C, Jaiyindee S, Thamlikitkul V. Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2008 29 2 131-136 (Pubitemid 351269208)
72. Kola A, Gastmeier P. Efficacy of oral chlorhexidine in preventing lower respiratory tract infections: meta-analysis of randomized controlled trials. J Hosp Infect 2007 66 3 207-216 (Pubitemid 46979844)
73. Chlebicki M P., Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2007 35 2 595-602 (Pubitemid 46148554)
74. Bratzler D W., Houck P M., Workgroup SIPGW Surgical Infection Prevention Guidelines Writers Workgroup American Academy of Orthopaedic Surgeons American Association of Critical Care Nurses American Association of Nurse Anesthetists American College of Surgeons American College of Osteopathic Surgeons American Geriatrics Society American Society of Anesthesiologists American Society of Colon and Rectal Surgeons American Society of Health-System Pharmacists American Society of PeriAnesthesia Nurses Ascension Health Association of periOperative Registered Nurses Association for Professionals in Infection Control and Epidemiology Infectious Diseases Society of America Medical Letter Premier Society for Healthcare Epidemiology of America Society of Thoracic Surgeons Surgical Infection Society. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004 38 12 1706-1715 (Pubitemid 38781662)
75. The Joint Commission. Available at: http://www.outcome.com/provider- joint-commission.htm Accessed September 9, 2010
76. Bratzler D W., Houck P M., Richards C et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005 140 2 174-182 (Pubitemid 40229109)
77. Burke J F. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961 50 161-168
78. Stone H H., Hooper C A., Kolb L D., Geheber C E., Dawkins E J. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg 1976 184 4 443-452
79. Classen D C., Evans R S., Pestotnik S L., Horn S D., Menlove R L., Burke J P. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992 326 5 281-286
80. Terpstra S, Noordhoek G T., Voesten H G., Hendriks B, Degener J E. Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis. J Hosp Infect 1999 43 3 195-202
81. Harbarth S, Samore M H., Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000 101 25 2916-2921 (Pubitemid 30415881)
82. Hoth J J., Franklin G A., Stassen N A., Girard S M., Rodriguez R J., Rodriguez J L. Prophylactic antibiotics adversely affect nosocomial pneumonia in trauma patients. J Trauma 2003 55 2 249-254 (Pubitemid 37047392)
83. Smith D W. Decreased antimicrobial resistance following changes in antibiotic use. Surg Infect (Larchmt) 2000 1 1 73-78
84. Nicastri E, Leone S, Petrosillo N et al. Decrease of methicillin resistant Staphylococcus aureus prevalence after introduction of a surgical antibiotic prophylaxis protocol in an Italian hospital. New Microbiol 2008 31 4 519-525
85. Meyer E, Schwab F, Pollitt A, Bettolo W, Schroeren-Boersch B, Trautmann M. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. Infection 2010 38 1 19-24